WUHAN and SAN DIEGO, Jul. 29, 2022 – MIT Technology Review released
the MIT 50 Smartest Companies (TR50) of the year 2021. Neurophth
Therapeutics, Inc., (“Neurophth”) is one of the award winners.
MIT Technology Review has picked “50 Smart Companies” from
thousands of technology companies around the world to share its insights into
the future of technology each year since 2010. The 50 Smartest Companies list
was created to recognize companies that best combine innovative technology with
an effective business model. It demonstrates the innovative breakthroughs and
the significant impact that emerging technologies bring to China and the world.
Neurophth is China’s leading in-vivo gene therapy company for ophthalmic
diseases. With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and US (San
Diego, California), Neurophth, a fully integrated company, is striving to
discover and develop genomic medicines for patients suffering from genetic
diseases globally. Our validated AAV platform, which has been published in Nature
- Scientific Reports, Ophthalmology, and EBioMedicine, has
successfully delivered proof-of-concept investigator-initiated trials data of
186 subjects with investigational gene therapies in the retina.
Our most advanced investigational gene
therapy drug candidate, NR082 (rAAV2-ND4), in development for the
treatment of mtND4-mediated LHON, has been granted orphan drug
designation (ODD) by the U.S. FDA and EMA. After the IND clearance by the China
NMPA in March 2021 and the U.S. IND by FDA in January 2022, Neurophth has
successfully completed an EOP2 meeting with CDE and reached an agreement on the
design of the Phase III clinical trial. The pipeline also includes mtND1-mediated
LHON (the Company’s 2nd US ODD), autosomal dominant optic atrophy, optic
neuroprotection, vascular retinopathy, and five other preclinical candidates.
Neurophth has scaled up in-house manufacturing capability in Suzhou facility
utilizing single-use technologies to support future commercial demand. To learn
more about us and our growing pipeline, visit www.neurophth.com.